Sarcoma Clinical Trials

64 studies are recruiting for sarcoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors

   The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.

   Stage

   Not phased

   Ages

   18 to 39

   Site

   Duke Cancer Institute, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT06371768 on ClinicalTrials.gov

2. HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

   The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this therapy might help patients with sarcoma. Another goal of this study is…

   Stage

   Phase 1

   Ages

   1 to 25

   Site

   Texas Children's Hospital, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT04995003 on ClinicalTrials.gov

3. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

   This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

   Stage

   Not phased

   Ages

   40 and older

   Site

   City of Hope, Duarte, California

   Locations

   17 in total

   Run by

   Adela, Inc

   See if you can join NCT05366881 on ClinicalTrials.gov

4. PROMIS and Mobility Evaluation in Sarcoma Patients

   The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study include to: 1. Validate PROMIS as a patient outcome measure in sa…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Foothills Medical Centre, Arthur J Child Comprehensive Cancer Centre, University of Calgary, Calgary, Alberta

   Locations

   4 in total

   Run by

   University of Calgary

   See if you can join NCT07227961 on ClinicalTrials.gov

5. Pediatric Radiation Therapy Registry

   The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term outcomes and toxicity of each patient. The registry will ca…

   Stage

   Not phased

   Ages

   0 to 26

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT07129317 on ClinicalTrials.gov

6. WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

   The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG)…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07058064 on ClinicalTrials.gov

7. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

   This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   9 in total

   Run by

   ImmVira Pharma Co. Ltd

   See if you can join NCT04370587 on ClinicalTrials.gov

8. Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

   A phase 2 study assessing the efficacy of all-trans retinoic acid (ATRA) and Cemiplimab in patients with metastatic/locally advanced - unresectable leiomyosarcoma (LMS) who have progressed standard-of-care therapy. Patients will be enrolled in cohorts according to a Bayesian Optimal Phase II design…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Gabriel Tinoco

   See if you can join NCT06528769 on ClinicalTrials.gov

9. Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan

   This study evaluates the impact that a sarcoma diagnosis and treatment have had on patients over time.

   Stage

   Not phased

   Ages

   Any age

   Site

   Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT06482957 on ClinicalTrials.gov

10. A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

    This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have…

    Stage

    Phase 2

    Ages

    1 to 40

    Site

    Children's Hospital of Alabama/UAB, Birmingham, Alabama

    Locations

    6 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05135975 on ClinicalTrials.gov

11. 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

    This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patient…

    Stage

    Phase 1

    Ages

    15 and older

    Site

    City of Hope, Duarte, California

    Locations

    5 in total

    Run by

    Lantheus Medical Imaging

    See if you can join NCT06298916 on ClinicalTrials.gov

12. Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

    RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT00005095 on ClinicalTrials.gov

13. Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

    This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sarcoma Oncology Center, Santa Monica, California

    Run by

    Sarcoma Oncology Research Center, LLC

    See if you can join NCT03886311 on ClinicalTrials.gov

14. BostonGene and Exigent Genomic INsight Study

    The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Highlands Oncology Group, Rogers, Arkansas

    Locations

    7 in total

    Run by

    BostonGene

    See if you can join NCT06272864 on ClinicalTrials.gov